ASH 2021 AML In-depth

MDS/CMML With KMT2A Rearrangements ‘Should Be Classified as AML’

There was no difference in overall survival between patients with MDS/CMML and those with AML.

Triplet Improves Outcomes in Older Patients With FLT3-Mutated Acute Myeloid Leukemia

Response rates and overall survival were superior in the triplet group.

Black AYAs With AML Have Worse Outcomes Than White Counterparts

The disparity was driven by patients aged 18-29 years.

Gilteritinib Does Not Improve Survival in FLT3-Mutated AML

Most outcomes were similar for patients who received gilteritinib plus azacitidine and those who received azacitidine alone.

Cardiac Events Seen in One-Fifth of AML Patients on Venetoclax Plus HMAs

Most events occurred during treatment cycles 1 and 2.

Women With AML Have Worse Outcomes With Gemtuzumab Ozogamicin

GO plus cytarabine was no more effective than standard chemotherapy and appeared particularly detrimental for women.